MeiraGTx Holdings plc (MGTX)

USD 5.84

(-8.75%)

Market Cap (In USD)

456.41 Million

Revenue (In USD)

14.01 Million

Net Income (In USD)

-84.02 Million

Avg. Volume

197.54 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
3.85-7.6
PE
-
EPS
-
Beta Value
1.247
ISIN
KYG596651029
CUSIP
G59665102
CIK
1735438
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Alexandria Forbes Ph.D.
Employee Count
-
Website
https://www.meiragtx.com
Ipo Date
2018-06-08
Details
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.